Unites companies from healthcare and life sciences
Velsera at a glance
Velsera is a consolidation of three leading companies within digital diagnostics, bioinformatics, healthcare data and advanced analytics enabling better healthcare, diagnostics, and precision medicine. It unites Seven Bridges, Pierian and UgenTec to advance and accelerate the work of both domains. All companies remain actively engaged with existing customers, enhance current offerings, accelerate new offerings, and bring integrated solutions to market as leading providers of global omics and insights.
- Year acquired
- 2022
- Location
- Boston
- Employees
- 586
- Website
- https://www.velsera.com
- Investment theme
- Changing Demographics
- Contact
- tommi.unkuri@summaequity.com
UgenTec brings sample flow intelligence to advance modern molecular diagnostics across routine and research applications. UgenTec software and AI solutions deliver workflow automation, result calling at scale and real-time insights for the digital, connected lab.
Pierian is a global leader in clinical genomics technology and services supporting a network of laboratories around the globe. Pierian curates the world’s genetic knowledge and offers sophisticated analysis tools to allow for rapid, concise clinical reporting. Its advanced interpretation technology uses adaptive learning algorithms to connect diverse sources of information through machine learning to ensure NGS results are comprehensive and up to date.
Seven Bridges enables researchers to extract meaningful insights from multiomic, phenotypic and other high throughput data modalities. The Seven Bridges ecosystem consists of a scalable, secure multi-cloud analytic platform, petabytes of connected biomedical data and expert on-demand professional services.
What are the challenges Velsera addresses
-
9.2%
of OECD GDP was spent on healthcare
-
20%
of healthcare spending is wasted
How does Velsera help?
Reality today
Healthcare systems face great challenges in patient outcome quality and waste related to ineffective treatments. The ongoing shift to precision medicine is a momentous change in healthcare.
Approach
Velsera powers the ecosystem of insight from healthcare and life sciences with data made actionable by AI and technology solutions that accelerate R&D, democratize omics and provide bedside analytics to improve patient outcomes.
Aspirational future
A connected healthcare and life sciences, revealing the true promise of precision medicine – a continuous flow of knowledge between researchers, scientists, and clinicians around the world, creating insights that radically improve human health.
Who is impacted?
Velsera’s customers are primarily (bio)pharma, biotech, clinical diagnostics companies, healthcare providers and academia in the US and Europe. The group is trusted by 9 out of 10 top biopharma as well as national governments to power secure discovery using health and omics data. By providing data driven insights, Velsera also enables its customers to accelerate better care for patients.
Contribution
The Velsera Group uniquely enables healthcare and life sciences actors to drive development in healthcare, diagnostics and precision medicine faster and at a lower cost through their data driven solutions, ultimately contributing to positive patient impacts.
Risks
Quality of data, insights and analytical capabilities will be critical for Velsera to deliver on. If Velsera cannot deliver the required quality, its customers will likely stop using its products, slowing down the data driven development in healthcare, diagnostics, and precision medicine.
